196 related articles for article (PubMed ID: 9060707)
1. Truncation of the human immunodeficiency virus type 1 envelope glycoprotein allows efficient pseudotyping of Moloney murine leukemia virus particles and gene transfer into CD4+ cells.
Mammano F; Salvatori F; Indraccolo S; De Rossi A; Chieco-Bianchi L; Göttlinger HG
J Virol; 1997 Apr; 71(4):3341-5. PubMed ID: 9060707
[TBL] [Abstract][Full Text] [Related]
2. Truncation of the human immunodeficiency virus-type-2 envelope glycoprotein allows efficient pseudotyping of murine leukemia virus retroviral vector particles.
Höhne M; Thaler S; Dudda JC; Groner B; Schnierle BS
Virology; 1999 Aug; 261(1):70-8. PubMed ID: 10441556
[TBL] [Abstract][Full Text] [Related]
3. Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses.
Sandrin V; Muriaux D; Darlix JL; Cosset FL
J Virol; 2004 Jul; 78(13):7153-64. PubMed ID: 15194792
[TBL] [Abstract][Full Text] [Related]
4. Rescue of human immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic domains.
Mammano F; Kondo E; Sodroski J; Bukovsky A; Göttlinger HG
J Virol; 1995 Jun; 69(6):3824-30. PubMed ID: 7745730
[TBL] [Abstract][Full Text] [Related]
5. A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy, and sense RNAs, and trans-dominant negative mutant Gag and Env proteins.
Ding SF; Lombardi R; Nazari R; Joshi S
Front Biosci; 2002 Feb; 7():a15-28. PubMed ID: 11815282
[TBL] [Abstract][Full Text] [Related]
6. Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein.
Dorfman T; Mammano F; Haseltine WA; Göttlinger HG
J Virol; 1994 Mar; 68(3):1689-96. PubMed ID: 8107229
[TBL] [Abstract][Full Text] [Related]
7. Replacement of the murine leukemia virus (MLV) envelope gene with a truncated HIV envelope gene in MLV generates a virus with impaired replication capacity.
Nack U; Schnierle BS
Virology; 2003 Oct; 315(1):209-16. PubMed ID: 14592772
[TBL] [Abstract][Full Text] [Related]
8. Targeted infection of a retrovirus bearing a CD4-Env chimera into human cells expressing human immunodeficiency virus type 1.
Matano T; Odawara T; Iwamoto A; Yoshikura H
J Gen Virol; 1995 Dec; 76 ( Pt 12)():3165-9. PubMed ID: 8847525
[TBL] [Abstract][Full Text] [Related]
9. Specific interactions between retrovirus Env and Gag proteins in rat neurons.
Weclewicz K; Ekström M; Kristensson K; Garoff H
J Virol; 1998 Apr; 72(4):2832-45. PubMed ID: 9525603
[TBL] [Abstract][Full Text] [Related]
10. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions.
Freed EO; Martin MA
J Virol; 1996 Jan; 70(1):341-51. PubMed ID: 8523546
[TBL] [Abstract][Full Text] [Related]
11. Pseudotyping of Moloney leukemia virus-based retroviral vectors with simian immunodeficiency virus envelope leads to targeted infection of human CD4+ lymphoid cells.
Indraccolo S; Minuzzo S; Feroli F; Mammano F; Calderazzo F; Chieco-Bianchi L; Amadori A
Gene Ther; 1998 Feb; 5(2):209-17. PubMed ID: 9578840
[TBL] [Abstract][Full Text] [Related]
12. Infectious particles derived from Semliki Forest virus vectors encoding murine leukemia virus envelopes.
Lebedeva I; Fujita K; Nihrane A; Silver J
J Virol; 1997 Sep; 71(9):7061-7. PubMed ID: 9261436
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions.
Yu X; Yuan X; McLane MF; Lee TH; Essex M
J Virol; 1993 Jan; 67(1):213-21. PubMed ID: 8416370
[TBL] [Abstract][Full Text] [Related]
14. Production and characterization of simian--human immunodeficiency virus-like particles.
Yao Q; Kuhlmann FM; Eller R; Compans RW; Chen C
AIDS Res Hum Retroviruses; 2000 Feb; 16(3):227-36. PubMed ID: 10710211
[TBL] [Abstract][Full Text] [Related]
15. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1.
Stitz J; Buchholz CJ; Engelstädter M; Uckert W; Bloemer U; Schmitt I; Cichutek K
Virology; 2000 Jul; 273(1):16-20. PubMed ID: 10891403
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the matrix protein of human immunodeficiency virus type 1 inhibit surface expression and virion incorporation of viral envelope glycoproteins in CD4+ T lymphocytes.
Lee YM; Tang XB; Cimakasky LM; Hildreth JE; Yu XF
J Virol; 1997 Feb; 71(2):1443-52. PubMed ID: 8995670
[TBL] [Abstract][Full Text] [Related]
17. The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses.
Bour S; Strebel K
J Virol; 1996 Dec; 70(12):8285-300. PubMed ID: 8970948
[TBL] [Abstract][Full Text] [Related]
18. Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase.
Kräusslich HG; Ochsenbauer C; Traenckner AM; Mergener K; Fäcke M; Gelderblom HR; Bosch V
Virology; 1993 Feb; 192(2):605-17. PubMed ID: 8421902
[TBL] [Abstract][Full Text] [Related]
19. Two distinct oncornaviruses harbor an intracytoplasmic tyrosine-based basolateral targeting signal in their viral envelope glycoprotein.
Lodge R; Delamarre L; Lalonde JP; Alvarado J; Sanders DA; Dokhélar MC; Cohen EA; Lemay G
J Virol; 1997 Jul; 71(7):5696-702. PubMed ID: 9188652
[TBL] [Abstract][Full Text] [Related]
20. Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice.
Wong SB; Siliciano RF
J Virol; 2005 Feb; 79(3):1701-12. PubMed ID: 15650195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
